Contact tracing issues for the Memphis Grizzlies meant they would not have enough players eligible to play in Portland on Wednesday night, leading to the 16th game postponement for coronavirus-related reasons by the NBA this season. Of those, 15 have come since Jan. 10 and the number could rise again soon: Memphis is scheduled to play in Portland on Friday as well. Starting with Wednesday’s games, the NBA told teams to have their security officials “stationed near the half-court line during pre-game warmups and post-game to provide reminders to players and staff and encourage compliance” with the rules regarding interaction.
Twitter had fun with Amy Poehler’s beloved character, who once described her ideal man as “having the brains of George Clooney in the body of Joe Biden.”
President left motorcade despite threats of violence
Chiesa won by the score of 49-46, or four rounds to one, on all three official scorecards.
Researchers from universities in China collaborated on the study, which found that 114g of fried food, equivalent to a medium portion of French fries, could have serious long-term health implications. They pooled data from 23 studies, which
Dozens of merchants protested Wednesday in Colombia’s capital city of Bogota against the local government’s restrictions meant to stop the spread of the coronavirus. Thousands of companies in Bogota ceased operations in 2020, according to the Observatory for COVID Monitoring and Reactivation. Bogota Mayor Claudia López has said the restrictions are in response to an increase in COVID-19 infections and the high occupancy of hospital intensive care units.
MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on January 7, 2021 a capital increase of 262,812 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 49,427,200.33 EUR and is represented by 14,132,832 shares. This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions. FIGURES – MODIFIED on 8 JANUARY 2021 following the CAPITAL INCREASE Total amount of share capital (EUR)49,427,200.33Total number of shares with single voting rights14,132,832Total number of shares with double voting rights72,324Total number of shares14,205,156Total number of voting rights14,277,480Total number of attributed warrants1,488,006Total number of shares with voting rights that could be created following the exercise of the attributed warrants1,488,006Total number of diluted shares (outstanding shares + warrants)15,693,162Total number of diluted shares with voting rights15,765,486 Contact person for regulated information (financial, transparency) By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): firstname.lastname@example.org. Further questions about the content of this release can be sent to email@example.com. About Celyad Oncology Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Forward-looking statements This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the clinical activity of CYAD-101. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty include the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. Investor and Media Contacts: Sara ZelkovicCommunications & Investor Relations DirectorCelyad Oncology firstname.lastname@example.org Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com Source: Celyad Oncology SA
Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd.
Easterly Government Properties, Inc. (NYSE: DEA) ("Easterly" or the "Company"), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced the tax characteristics of the 2020 distributions on its common stock. The tax reporting will be done on Form 1099-DIV and shareholders are encouraged to consult with their personal tax advisors as to the specific tax treatment of these distributions. The characteristics of the Company's distributions are as follows:
NextDecade Announces Appointment of Brent Wahl as Chief Financial Officer
The New Home Company (NYSE: NWHM) today announced that the Company will release its financial results for the fourth quarter and full year 2020 before the market opens on Thursday, February 11, 2021. The Company will also host a conference call for investors and other interested parties beginning at 8:00 AM Pacific Time (11:00 AM Eastern Time) on that same day to review the results, discuss recent events and conduct a question-and-answer period.
Sonos, Inc. (Nasdaq: SONO) today announced that after market close on Wednesday, February 10, 2021 the company will report financial results for the first quarter ended January 2, 2021. The company will issue a press release and accompanying slide presentation at that time which will be accessible at https://investors.sonos.com/reports-and-filings/default.aspxsection=earningsreports.
Kinder Morgan, Inc.’s (NYSE: KMI) board of directors today approved a cash dividend of $0.2625 per share for the fourth quarter ($1.05 annualized), payable on February 16, 2021, to common stockholders of record as of the close of business on February 1, 2021. This dividend represents a 5% increase over the fourth quarter of 2019.
Limestone Bancorp, Inc. (NASDAQ: LMST) ("the Company"), parent company of Limestone Bank ("the Bank"), today reported unaudited results for the fourth quarter and full year of 2020. Net income available to common shareholders for the fourth quarter of 2020 was $3.1 million, or $0.42 per basic and diluted common share, compared with $1.8 million, or $0.24 per basic and diluted share, for the fourth quarter of 2019. Net income for the twelve months ended December 31, 2020, was $9.0 million, or $1.20 per diluted common share, compared with net income of $10.5 million, or $1.41 per diluted share, for the twelve months ended December 31, 2019.
Utz Brands, Inc. (NYSE: UTZ) ("Utz" or the "Company"), announced today the closing of its term loan refinancing. Initially contemplated as a $310 million add-on to the existing Term Loan B due 2024, following robust investor demand, Utz placed a new $720 million Term Loan B due 2028 (the "New Term Loan"), enabling the Company to extend its maturity profile and reset certain terms of its credit agreement. The New Term Loan, together with approximately $181 million in cash proceeds received from the redemption of all outstanding public warrants and forward purchase warrants, repaid in full the $490 million Bridge Credit Facility used to fund the acquisition of Truco Enterprises and the On The Border® brand, as well as refinanced the pre-existing $410 million Term Loan B due 2024.
QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus
The moment reflected a similar moment Biden and Roker shared during the 2013 inaugural parade
'Few people in our nation's history have been more challenged or found a time more challenging or difficult than the time we're in now,' says 46th president
Netflix star slams president for granting clemency to ‘corrupt friends’ instead of him
The stories of Beau, Hunter, Naomi and Ashley Biden